Monument, Therapeutics

Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia

Veröffentlicht: 07.08.2025 um 18:08 Uhr, prnewswire.co.uk

Monument Therapeutics United Kingdom England

View original content:https://www.prnewswire.co.uk/news-releases/monument-therapeutics-launches-first-clinical-study-of-mt1988-a-novel-treatment-for-cognitive-impairment-associated-with-schizophrenia-302315484.html

en | boerse | 67925076 |